RFK Jr. Criticizes FDA’s Shift on Promising Autism Drug Leucovorin
Recently, Robert F. Kennedy Jr. criticized the FDA’s recent decision regarding leucovorin, a drug initially hailed as a potential treatment for autism. This shift reflects a stark contrast to earlier government endorsements. Six months ago, health officials, including Kennedy, suggested leucovorin could offer significant benefits for children with autism.
FDA Approves Leucovorin for Cerebral Folate Deficiency
On Tuesday, the FDA granted approval for leucovorin to treat cerebral folate deficiency, a rare condition linked to some autism cases. However, the FDA did not endorse its use for autism itself, citing insufficient evidence to support such claims.
Details on Leucovorin
- Leucovorin, also known as folinic acid, is a form of folate (vitamin B9).
- Folate is crucial for fetal development and preventing neural tube defects.
- Leucovorin has been widely used to alleviate side effects from certain chemotherapy drugs.
While leucovorin can raise brain folate levels, its efficacy in treating autism remains uncertain. Research indicates that low brain folate levels might correlate with autism symptoms, but credible studies have been lacking.
Initial Enthusiasm and Subsequent Disappointment
In September, the Trump administration announced leucovorin as a major breakthrough for autism treatment. High-profile officials claimed it could assist a substantial number of children, with FDA commissioner Marty Makary suggesting it might benefit “hundreds of thousands.” This enthusiasm has since faded as the FDA acknowledged the drug’s approved use is only for the rare genetic form of cerebral folate deficiency.
Concerns About Evidence and Studies
Research supporting leucovorin for autism treatment has diminished. Earlier this year, a significant trial involving 77 children was retracted due to numerous data issues. In late January, further analysis revealed serious flaws in the evidence linking leucovorin to autism treatment.
The FDA reiterated its stance: there is not enough evidence to substantiate a broader autism application for leucovorin. Despite this, there have been increasing prescriptions for leucovorin following the initial announcements.
Future Directions
The FDA is encouraging further studies to explore leucovorin’s potential benefits for autism. However, it remains unclear whether any pharmaceutical companies will pursue this research. GlaxoSmithKline, the drug’s original manufacturer, had sought a label update at the FDA’s suggestion but later decided against marketing it as an autism treatment.
While some families may turn to leucovorin as an off-label treatment due to the earlier buzz, the lack of strong FDA endorsement raises questions about its future as a viable autism therapy. Without solid evidence, leucovorin risks becoming just another passing trend in autism treatment.
